worldwide offices | contact | help | sitemap
Diseases & products
Diseases & products home
About Novartis Vaccines
About Novartis Vaccines home
Novartis Vaccines history
Novartis Vaccines educational grants
Business development home
About the Business Development & Licensing group
Our areas of interest
Meningococcal Disease Press Kit
Seasonal Influenza Press Kit
Cultures & values
Diversity & inclusion
Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million.
Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B.
Learn about meningitis, influenza, rabies, TBE and japanese encephalities.
Learn the diseases and the vaccines that prevent them
Novartis Vaccines is the world's fifth-largest vaccines business.
Learn about our mission, business and people
See stock performance